Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGMT vs VNDA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGMT Captures Overall Composite Edge (43.1 HOLD vs 49.0 HOLD), While VNDA Leads 3–2 on Growth & Valuation Pillars
SGMT Overall Winner
6-Pillar Tally: SGMT 2 – 3 VNDA (1 Tie)
Matrix Metrics: SGMT 5 – 5 VNDA
As of Nov 16, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (43.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $10.29 (N/M Forward P/E, 0.0% operating margin) versus VNDA at $3.79 (103.1x Forward P/E, -77.6% operating margin).
- Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. SGMT 43.1/100 HOLD), SGMT captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -77.6% operating margin) and revenue trajectory (+0.0% vs. +24.1% YoY).
- Technical & Structure Timing Caution: SGMT trades in a Neutral technical trend (BREAKOUT options phase, RSI 51.5); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SGMT vs VNDA
SGMT
Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
$10.29
+0.68% 1D
Market Cap
$775.0M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.05β · 84% Vol
Unified Composite Score
43.1
HOLD
Tech 15.0
Fund 46.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
VNDA
Vanda Pharmaceuticals Inc.
$3.79
-4.89% 1D
Market Cap
$238.9M
TTM Revenue
$229M
Forward P/E
103.1x
Beta / 30D Vol
1.25β · 61% Vol
Unified Composite Score
49.0
HOLD
Tech 56.0
Fund 58.0
Flow 65.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SGMT 2 – 3 VNDA)
1. Valuation Multiples
VNDA
Forward P/E
N/M
103.1x
Trailing P/E
N/M
103.1x
PEG Ratio
N/M
2.23x
EV / Revenue
N/M
0.9x
2. Growth & Scale
VNDA
Revenue Growth (YoY)
+0.0%
+24.1%
Earnings Growth (YoY)
+0.0%
-95.9%
TTM Revenue (USD)
N/A
$229M
Market Cap
$775.0M
$238.9M
3. Profitability & Quality
SGMT
Gross Margin
N/A
93.6%
Operating Margin
0.0%
-77.6%
Net Profit Margin
0.0%
-119.9%
Return on Equity (ROE)
-24.4%
-82.5%
4. Balance Sheet & Cash Flow
VNDA
Cash Generation (TTM)
-$44M
-$150M
Cash Flow Margin
N/A
-65.4%
Net Cash / Leverage
$109M Net Cash
$40M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGMT
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
83.2% (5th %ile)
163.3% (75th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGMT (5) vs VNDA (5)| Institutional Metric | SGMT | VNDA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $775.0M | $238.9M | SGMT | |
| Trailing P/E Ratio | N/M | 103.1x | VNDA | |
| Forward P/E Ratio | N/M | 103.1x | VNDA | |
| Revenue Growth (YoY) | +0.0% | +24.1% | VNDA | |
| Operating Margin (TTM) | 0.0% | -77.6% | SGMT | |
| Net Profit Margin | 0.0% | -119.9% | SGMT | |
| Return on Equity (ROE) | -24.4% | -82.5% | SGMT | |
| 52-Week Range Position | 83% ($4–$11) | 4% ($4–$10) | SGMT | |
| Beta / 30D Volatility | 2.05β · 84% Vol | 1.25β · 61% Vol | VNDA | |
| Unified Institutional Score | 43.1 / 100 (HOLD) | 49.0 / 100 (HOLD) | VNDA | |
| Trailing 12M Revenue (USD) | N/A | $229M | Scale | |
| Gross Profit Margin (TTM) | N/A | 93.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 2.23x PEG · 0.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$44M ($109M Net Cash) | -$150M ($40M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SGMT +34.13 pp
3M Horizon
SGMT +27.5 pp
6M Horizon
SGMT +92.08 pp
1Y Horizon
SGMT +45.51 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SGMT Revenue | VNDA Revenue | SGMT Op. Margin | VNDA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $190M | N/A | 11.3% | VNDA |
| FY2019 | N/A | $230M | N/A | 10.0% | VNDA |
| FY2020 | N/A | $250M | N/A | 11.0% | VNDA |
| FY2021 | N/A | $270M | N/A | 15.7% | VNDA |
| FY2022 | N/A | $250M | N/A | 2.5% | VNDA |
| FY2023 | $0M | $190M | -1537.0% | -7.2% | VNDA |
| FY2024 | N/A | $200M | N/A | -20.5% | VNDA |
| FY2025 | N/A | $220M | N/A | -70.0% | VNDA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SGMT
BREAKOUT
Current IV
83.2%
IV Percentile
5th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
VNDA
BREAKDOWN
Current IV
163.3%
IV Percentile
75th %ile
Put/Call OI Skew
N/A
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SGMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
VNDA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SGMT vs VNDA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (43.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $10.29 (N/M Forward P/E, 0.0% operating margin) versus VNDA at $3.79 (103.1x Forward P/E, -77.6% operating margin). Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. SGMT 43.1/100 HOLD), SGMT captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -77.6% operating margin) and revenue trajectory (+0.0% vs. +24.1% YoY). Technical & Structure Timing Caution: SGMT trades in a Neutral technical trend (BREAKOUT options phase, RSI 51.5); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VNDA leads the Growth & Scale pillar: SGMT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SGMT cumulative revenue shifted N/A while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, SGMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.
VNDA screens cheaper on headline valuation multiples. SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMT (-24.4% ROE) versus VNDA (-82.5% ROE) capital efficiency.
In options market volatility and institutional positioning, SGMT carries 83.2% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.05β · 84% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
VNDA vs SGMT · Reverse Pair
SGMT vs TVGN
· Sector Peer
SGMT vs ANNX
· Sector Peer
VNDA vs IRWD
· Sector Peer
VNDA vs SUPN
· Sector Peer
VNDA vs RIGL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem